- Home
- SAVA vs ECOR Comparison
SAVA vs ECOR Comparison
Compare SAVA & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- ECOR
- Stock Information
- Founded
- SAVA 1998
- ECOR 2005
- Country
- SAVA United States
- ECOR United States
- Employees
- SAVA N/A
- ECOR N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- SAVA Health Care
- ECOR Health Care
- Exchange
- SAVA Nasdaq
- ECOR Nasdaq
- Market Cap
- SAVA 135.9M
- ECOR 111.3M
- IPO Year
- SAVA N/A
- ECOR 2018
- Fundamental
- Price
- SAVA $2.75
- ECOR $15.90
- Analyst Decision
- SAVA Buy
- ECOR Strong Buy
- Analyst Count
- SAVA 3
- ECOR 1
- Target Price
- SAVA $111.50
- ECOR $25.00
- AVG Volume (30 Days)
- SAVA 3.4M
- ECOR 144.8K
- Earning Date
- SAVA 02-26-2025
- ECOR 03-12-2025
- Dividend Yield
- SAVA N/A
- ECOR N/A
- EPS Growth
- SAVA N/A
- ECOR N/A
- EPS
- SAVA N/A
- ECOR N/A
- Revenue
- SAVA N/A
- ECOR $23,327,000.00
- Revenue This Year
- SAVA N/A
- ECOR $59.81
- Revenue Next Year
- SAVA N/A
- ECOR $38.49
- P/E Ratio
- SAVA N/A
- ECOR N/A
- Revenue Growth
- SAVA N/A
- ECOR 74.10
- 52 Week Low
- SAVA $2.23
- ECOR $5.32
- 52 Week High
- SAVA $42.20
- ECOR $18.67
- Technical
- Relative Strength Index (RSI)
- SAVA 30.54
- ECOR 53.73
- Support Level
- SAVA $2.65
- ECOR $15.50
- Resistance Level
- SAVA $2.83
- ECOR $16.12
- Average True Range (ATR)
- SAVA 0.24
- ECOR 1.20
- MACD
- SAVA 0.59
- ECOR -0.31
- Stochastic Oscillator
- SAVA 52.75
- ECOR 40.17
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.